Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PROCEPT BioRoboticsPRCT -1.50%70 3-Year Book Growth Rate is 13.90% as of Jun. 2026, which is 38% above its 10-year median of 10.10. GuruFocus rates PRCT with a GF Score™ of 70/100 and a GF Value™ of $83.94 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 762 Medical Devices & Instruments companies, PROCEPT BioRobotics ranks better than 81.5% on this metric.
During the past 12 months, PROCEPT BioRobotics's average Book Value per Share Growth Rate was -14.40% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 13.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 7 years, the highest 3-Year average Book Value per Share Growth Rate of PROCEPT BioRobotics was 13.90% per year. The lowest was 6.30% per year. And the median was 10.10% per year.
PROCEPT BioRobotics (NAS:PRCT) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
PROCEPT BioRobotics 3-Year Book Growth Rate Related Terms
PRCT vs INMD, LMRI, QDEL: 3-Year Book Growth Rate Comparison
For the Medical Devices subindustry, PROCEPT BioRobotics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PROCEPT BioRobotics 3-Year Book Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PROCEPT BioRobotics's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where PROCEPT BioRobotics's 3-Year Book Growth Rate falls into.
PROCEPT BioRobotics 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 13.90% mean?
PROCEPT BioRobotics (PRCT) has a 3-Year Book Growth Rate of 13.90% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for PROCEPT BioRobotics and its competitors. This is 38% above median its historical median of 10.10. Over the past decade, PROCEPT BioRobotics' 3-Year Book Growth Rate has ranged from 6.30 to 13.90. According to the industry distribution chart, PROCEPT BioRobotics ranks #141 out of 762 companies in the Medical Devices & Instruments industry, placing it in the top 18.5%.
Is PROCEPT BioRobotics' 3-Year Book Growth Rate too high?
PROCEPT BioRobotics' current 3-Year Book Growth Rate of 13.90% is 38% above median its 10-year median of 10.10. Over the past 10 years, this metric has ranged from a low of 6.30 to a high of 13.90. The Medical Devices & Instruments industry median 3-Year Book Growth Rate is 2.35. PROCEPT BioRobotics' value of 13.90% is 491.5% above this industry median. Based on the distribution chart, PROCEPT BioRobotics ranks #141 out of 762 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, PROCEPT BioRobotics has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PROCEPT BioRobotics' 3-Year Book Growth Rate compare to INMD and LMRI?
According to the Medical Devices & Instruments industry distribution chart, PROCEPT BioRobotics ranks #141 out of 762 companies for 3-Year Book Growth Rate. This places PROCEPT BioRobotics in the top 19% of its industry — outperforming the majority of peers. The industry median 3-Year Book Growth Rate is 2.35. PROCEPT BioRobotics' value of 13.90% is 491.5% above this benchmark. Historically, PROCEPT BioRobotics' own 3-Year Book Growth Rate has ranged from 6.30 to 13.90 over the past decade. While the company's 10-year median is 10.10 vs. the industry median of 2.35, PROCEPT BioRobotics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Medical Devices & Instruments company?
The median 3-Year Book Growth Rate among Medical Devices & Instruments companies is 2.35, based on 762 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Book Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PROCEPT BioRobotics's current 3-Year Book Growth Rate of 13.90% is 491.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for PROCEPT BioRobotics and its competitors. For the Medical Devices & Instruments industry, the median 3-Year Book Growth Rate is 2.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PROCEPT BioRobotics's current 3-Year Book Growth Rate is 13.90%, which is 38% above median its own 10-year median of 10.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROCEPT BioRobotics stock overvalued right now?
Based on GuruFocus' analysis, PROCEPT BioRobotics (PRCT) is currently considered Significantly Undervalued. The stock's GF Value™ is $83.94, compared to a current price of $21.66 — trading 74.2% below its estimated fair value. The current 3-Year Book Growth Rate is 13.90%, which is 38% above median its 10-year median of 10.10 and 491.5% above the Medical Devices & Instruments industry median of 2.35. PROCEPT BioRobotics' overall GF Score™ is 70/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For PROCEPT BioRobotics (PRCT), the current 3-Year Book Growth Rate is 13.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PROCEPT BioRobotics (PRCT) Overvalued in 2026?
Based on GuruFocus' analysis, PROCEPT BioRobotics stock appears to be undervalued.
The current stock price of $21.66 is trading 74.2% below its estimated GF Value™ of $83.94.
GuruFocus considers PROCEPT BioRobotics to be Significantly Undervalued.
Key valuation signals for PRCT:
3-Year Book Growth Rate: 13.90% (38% above median its 10-year median of 10.10)
GF Value™: $83.94 vs. price of $21.66 (74.2% below fair value)
Industry Position: 491.5% above the Medical Devices & Instruments median (#141 of 762)
No single metric tells the full story. See the PRCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
70GF Score
Get the complete analysis for PRCT
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRCT has been successfully added to your 
